Winguide Huangpu Pharmaceutical

Shanghai Winguide Huangpu Pharmaceutical Company Limited specializes in the manufacturing of a diverse range of pharmaceutical preparations, including tinctures, ear drops, nose drops, powders, pastes, solutions, eye drops, ointments, and creams. Founded in 2012 and based in Shanghai, China, the company focuses on producing and selling topical medicine series, covering various topical preparations. It operates as a subsidiary of Winguide Far East Limited, reinforcing its commitment to quality and innovation within the pharmaceutical industry.

Yao Liang

Investment Director

4 past transactions

Bintie Biotechnology

Series A in 2023
Bintie Biotechnology is a pioneering biomedical technology enterprise in the clinical stage. Its primary products are novel immune cell formulations intended to target solid tumors.

Caprico Biotechnologies

Seed Round in 2023
Caprico Biotechnologies is a biotechnology company focused on developing and providing flow cytometry reagents and services for various applications, including basic and clinical research and diagnostics. The company specializes in immunophenotyping products, offering a range of ASR reagents tailored for T-cell clonality and non-human primate primary antibodies. Additionally, Caprico provides custom assay design and development services, as well as the production and conjugation of antibodies specifically for flow cytometry applications. Through its innovative solutions, Caprico Biotechnologies aims to enhance the operational efficiency of researchers in the field.

Yixi Biotech

Seed Round in 2023
Yixi Biotech is a provider of solutions for the intestinal microbiology sector, focusing on providing solutions for the intestinal microbiology sector. It mainly distributes three research and development pipelines for diabetes, depression and tumor reconstitution after tumor chemotherapy, focusing on intestinal microbes and human body. Research on health mechanisms, research on intestinal microecology and intestinal immune microenvironment interaction mechanisms and disease intervention strategies, and research and development of alternative treatment protocols, synthetic biological strains and drugs for the treatment of intestinal microbial diseases.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.